Phase-2 multicenter study results of Ublituximab, a novel glycoengineered antiCD20 monoclonal Antibody (mAb), in patients with Relapsing Multiple Sclerosis (RMS)

被引：0
|
作者：
Fox, E. J. [1 ]
Lovett-Racke, A. [2 ]
Inglese, M. [3 ]
Shubin, R. [4 ]
Twyman, C. [5 ]
Eubanks, J. [6 ]
Mok, K. [6 ]
Su, W. [6 ]
机构：
[1] Cent Texas Neurol Consultants, Round Rock, TX USA
[2] Ohio State Univ, Microbial Infect & Immun, Columbus, OH 43210 USA
[3] Icahn Sch Med Mt Sinai, Neurol, New York, NY 10029 USA
[4] SC3 Res Grp, Neurol, Pasadena, CA USA
[5] Associates Neurol Clin Res, Lexington, KY USA
[6] TG Therapeut Inc, Autoimmune, New York, NY USA
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2018年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
O331
引用
收藏
页码：71 / 71
页数：1
相关论文
共 50 条
  • [1] Final results of a placebo controlled, Phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS).
    Fox, E.
    Lovett-Racke, A.
    Gormley, M.
    Liu, Y.
    Wray, S.
    Shubin, R.
    Petracca, M.
    Inglese, M.
    Power, S.
    Bosco, J.
    Mok, K.
    Weiss, M.
    Eubanks, J.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 87 - 87
  • [2] Open Label Extension (OLE) of Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS)
    Fox, Edward
    Wray, Sibyl
    Shubin, Richard
    Bosco, Jenna
    Weiss, Michael
    Power, Sean
    Mok, Koby
    Eubanks, James
    NEUROLOGY, 2019, 92 (15)
  • [3] Open Label Extension (OLE) of Phase 2 multicenter study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal Antibody (mAb), in patients with Relapsing forms of Multiple Sclerosis (RMS)
    Fox, E.
    Wray, S.
    Shubin, R.
    Mok, K.
    Power, S.
    Bosco, J.
    Weiss, M.
    Eubanks, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 105 - 105
  • [4] A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis
    Fox, Edward
    Lovett-Racke, Amy E.
    Gormley, Matthew
    Liu, Yue
    Petracca, Maria
    Cocozza, Sirio
    Shubin, Richard
    Wray, Sibyl
    Weiss, Michael S.
    Bosco, Jenna A.
    Power, Sean A.
    Mok, Koby
    Inglese, Matilde
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (03) : 420 - 429
  • [5] Long-term follow-up results from the phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing multiple sclerosis (RMS)
    Fox, E.
    Wray, S.
    Shubin, R.
    Lovett-Racke, A.
    Huang, D.
    Bass, A.
    Weiss, M.
    Power, S.
    Bosco, J.
    Mok, K.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 543 - 544
  • [6] Final Results of a Phase 2 Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with RMS
    Fox, Edward J.
    Lovett-Racke, Amy
    Gormley, Matthew
    Liu, Yue
    Petracca, Maria
    Inglese, Matilde
    Cocozza, Sirio
    Wray, Sibyl
    Shubin, Richard
    Bosco, Jenna A.
    Power, Sean A.
    Weiss, Michael
    Mok, Koby
    Eubanks, James L.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 49 - 49
  • [7] Preliminary results of Phase 2 Multicenter Study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of Multiple Sclerosis (RMS) demonstrates rapid and robust B cell depletion
    Lovett-Racke, Amy
    Liu, Yue
    Racke, Michael
    Shubin, Richard
    Wray, Sibyl
    Su, Wendy
    Eubanks, James
    Fox, Edward
    NEUROLOGY, 2017, 88
  • [8] Rapid and robust B-cell depletion in preliminary results of phase 2 multicenter study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal Antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS)
    Lovett-Racke, A.
    Liu, Y.
    Racke, M.
    Wray, S.
    Shubin, R.
    Su, W.
    Eubanks, J.
    Fox, E. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 511 - 511
  • [9] 6 Month Results of a Phase 2a Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Relapsing Multiple Sclerosis
    Fox, Edward J.
    Lovett-Racke, Amy
    Wray, Sibyl
    Racke, Michael K.
    Shubin, Richard
    Twyman, Cary
    Eubanks, James
    Su, Wendy
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 23 - 23
  • [10] Preliminary results of phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS) demonstrates rapid Gd-enhancing lesions decrease
    Inglese, M.
    Petracca, M.
    Cocozza, S.
    Wray, S.
    Racke, M.
    Shubin, R.
    Su, W.
    Eubanks, J.
    Fox, E.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 410 - 411
12345